|Articles|January 1, 2002

Leflunomide may be option for psoriatic arthritis

SAN FRANCISCO - The disease modifying antirheumatic drug (DMARD) leflunomide (Arava), approved for use in rheumatoid arthritis, may also be an effective therapy for recalcitrant psoriatic arthritis and psoriasis, according to two new studies.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME